100 CARDINAL WAY, REDWOOD CITY, CA
To Acquire Biotechnologies
Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration
Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights
News, Material Contracts
Earnings Release
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones
Material disclosure
Q2
Q1
FY 2024
Notice of Late Filing for Annual Report
FY 2023
Q3
Tender Offer Statement by Issuer
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership